These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24751319)

  • 61. [Association between health related quality of life and severity of depression in patients with major depressive disorder].
    Cao Y; Li W; Shen J; Zhang Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 36(2):143-8. PubMed ID: 21368424
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early improvement predicts outcome of major depressive patients treated with electroconvulsive therapy.
    Lin CH; Chen MC; Yang WC; Lane HY
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):225-233. PubMed ID: 26718791
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Patterns of symptom improvement during antidepressant treatment of delusional depression.
    Serretti A; Lattuada E; Zanardi R; Franchini L; Smeraldi E
    Psychiatry Res; 2000 May; 94(2):185-90. PubMed ID: 10808044
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.
    Lustman PJ; Freedland KE; Griffith LS; Clouse RE
    Diabetes Care; 2000 May; 23(5):618-23. PubMed ID: 10834419
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder.
    Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
    J Clin Psychopharmacol; 2011 Apr; 31(2):187-93. PubMed ID: 21346612
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial.
    Duan DM; Tu Y; Jiao S; Qin W
    Chin J Integr Med; 2011 Mar; 17(3):190-9. PubMed ID: 21359920
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation.
    Rizvi SJ; Salomons TV; Konarski JZ; Downar J; Giacobbe P; McIntyre RS; Kennedy SH
    J Affect Disord; 2013 Nov; 151(2):573-581. PubMed ID: 23948629
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder.
    Tao R; Emslie GJ; Mayes TL; Nakonezny PA; Kennard BD
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):423-30. PubMed ID: 20973713
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Behav Res Ther; 2016 Dec; 87():48-57. PubMed ID: 27591917
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study.
    Montoya A; Lebrec J; Keane KM; Fregenal I; Ciudad A; Moríñigo Á; Agüera-Ortiz L; Romera I; Gilaberte I; Zimmerman M
    BMC Psychiatry; 2016 Oct; 16(1):352. PubMed ID: 27760534
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study.
    Jha MK; Minhajuddin A; Chin-Fatt C; Greer TL; Carmody TJ; Trivedi MH
    J Psychiatr Res; 2019 Jun; 113():165-171. PubMed ID: 30959227
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial.
    Sonawalla SB; Farabaugh AH; Leslie VM; Pava JA; Matthews JD; Fava M
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Dec; 26(7-8):1415-9. PubMed ID: 12502032
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of serum cytokines levels in normal-weight and overweight patients with first-episode drug-naïve major depressive disorder.
    Gao W; Xu Y; Liang J; Sun Y; Zhang Y; Shan F; Ge J; Xia Q
    Front Endocrinol (Lausanne); 2022; 13():1048337. PubMed ID: 36387880
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database.
    Kraus C; Kautzky A; Watzal V; Gramser A; Kadriu B; Deng ZD; Bartova L; Zarate CA; Lanzenberger R; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fanelli G; Serretti A; Kasper S
    J Affect Disord; 2023 Aug; 335():349-357. PubMed ID: 37196934
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients.
    Achiron A; Barak Y; Noy S; Pinhas-Hamiel O
    Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):111-3. PubMed ID: 10082236
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effects of extended evaluation on depressive symptoms in children and adolescents.
    Rintelmann JW; Emslie GJ; Rush AJ; Varghese T; Gullion CM; Kowatch RA; Hughes CW
    J Affect Disord; 1996 Nov; 41(2):149-56. PubMed ID: 8961043
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Depression and pain impair daily functioning and quality of life in patients with major depressive disorder.
    Lin CH; Yen YC; Chen MC; Chen CC
    J Affect Disord; 2014 Sep; 166():173-8. PubMed ID: 25012428
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.
    Sit D; Perel JM; Luther JF; Wisniewski SR; Helsel JC; Wisner KL
    J Clin Psychopharmacol; 2010 Aug; 30(4):381-6. PubMed ID: 20631556
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Surrogate markers of visceral fat and response to anti-depressive treatment in patients with major depressive disorder: a prospective exploratory analysis.
    Tønning M; Petersen D; Steglich-Petersen M; Csillag C
    Nord J Psychiatry; 2017 Feb; 71(2):110-114. PubMed ID: 27701935
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status.
    Fourrier C; Sampson E; Hori H; Schubert KO; Clark S; Mills NT; Baune BT
    Brain Behav Immun; 2020 Aug; 88():242-251. PubMed ID: 32526448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.